Zentalis Pharmaceuticals, Inc. (ZNTL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1250726,
    "name": "Zentalis Pharmaceuticals, Inc.",
    "stock_name": "Zentalis Pharmaceuticals, Inc.",
    "full_name": "Zentalis Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/zentalis-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.40",
    "chg": 0.06,
    "chgp": "4.48%",
    "dir": 1,
    "prev_price": "1.34",
    "mcapval": "117.58",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US98943L1070",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.27 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zentalis-pharmaceuticals-inc-1250726-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zentalis-pharmaceuticals-forms-death-cross-signaling-bearish-trend-ahead-3726006",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZentalisPharmac_dealthcross_3726006.png",
        "date": "2025-11-24 15:17:45",
        "description": "Zentalis Pharmaceuticals, Inc. has encountered a significant technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has faced substantial declines over various timeframes, with a notable three-year drop of 93.66% and a five-year decline of 97.09%, reflecting ongoing challenges in the biotechnology sector."
      },
      {
        "title": "Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zentalis-pharmaceuticals-forms-death-cross-signaling-bearish-trend-ahead-3690280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ZentalisPharmac_dealthcross_3690280.png",
        "date": "2025-11-11 16:08:57",
        "description": "Zentalis Pharmaceuticals, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with significant declines over the past year and challenges in the competitive market, despite a brief one-day performance increase."
      },
      {
        "title": "Zentalis Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/zentalis-pharmaceuticals-forms-golden-cross-signaling-bullish-breakout-ahead-3651969",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ZentalisPharmac_goldencross_3651969.png",
        "date": "2025-10-28 14:57:21",
        "description": "Zentalis Pharmaceuticals has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose significantly today and over the past week, despite a challenging year-to-date performance. Technical indicators suggest a bullish outlook, prompting interest in the company's future trends and recovery potential."
      },
      {
        "title": "Is Zentalis Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zentalis-pharmaceuticals-inc-technically-bullish-or-bearish-3547913",
        "imagepath": "",
        "date": "2025-09-20 20:05:53",
        "description": "As of 8 September 2025, the technical trend for Zentalis Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a bearish stance. The Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The KST is bullish on a weekly basis, while the Dow Theory is mildly bearish. The OBV is also mildly bearish on the weekly timeframe. \n\nZentalis has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -50.83% versus the S&P 500's 12.22%, and a one-year return of -64.18% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish...."
      },
      {
        "title": "Is Zentalis Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zentalis-pharmaceuticals-inc-overvalued-or-undervalued-3544129",
        "imagepath": "",
        "date": "2025-09-20 18:38:36",
        "description": "As of 7 May 2024, Zentalis Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns regarding its valuation. The company appears to be overvalued, especially given its significant losses and poor performance metrics. Key ratios include a Price to Book Value of 0.37, an EV to EBIT of 1.12, and an EV to EBITDA of 1.13, which suggest that the company's valuation does not align well with its financial performance.\n\nIn comparison to peers, Zentalis Pharmaceuticals has a valuation of -0.7834, while Prothena Corp. Plc has a valuation of -1.6907, indicating that Zentalis is relatively better positioned but still in a risky category. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.83% compared to the index's 12.22%, reinforcing the notion that it is overvalued in its current state...."
      }
    ],
    "total": 10,
    "sid": "1250726",
    "stock_news_url": "https://www.marketsmojo.com/news/zentalis-pharmaceuticals-inc-1250726"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead

2025-11-24 15:17:45

Zentalis Pharmaceuticals, Inc. has encountered a significant technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has faced substantial declines over various timeframes, with a notable three-year drop of 93.66% and a five-year decline of 97.09%, reflecting ongoing challenges in the biotechnology sector.

Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead

2025-11-11 16:08:57

Zentalis Pharmaceuticals, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential shift in market sentiment. Current indicators reflect a bearish outlook, with significant declines over the past year and challenges in the competitive market, despite a brief one-day performance increase.

Zentalis Pharmaceuticals Forms Golden Cross, Signaling Bullish Breakout Ahead

2025-10-28 14:57:21

Zentalis Pharmaceuticals has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose significantly today and over the past week, despite a challenging year-to-date performance. Technical indicators suggest a bullish outlook, prompting interest in the company's future trends and recovery potential.

Is Zentalis Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 20:05:53

As of 8 September 2025, the technical trend for Zentalis Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a bearish stance. The Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The KST is bullish on a weekly basis, while the Dow Theory is mildly bearish. The OBV is also mildly bearish on the weekly timeframe. Zentalis has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -50.83% versus the S&P 500's 12.22%, and a one-year return of -64.18% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish....

Is Zentalis Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:38:36

As of 7 May 2024, Zentalis Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns regarding its valuation. The company appears to be overvalued, especially given its significant losses and poor performance metrics. Key ratios include a Price to Book Value of 0.37, an EV to EBIT of 1.12, and an EV to EBITDA of 1.13, which suggest that the company's valuation does not align well with its financial performance. In comparison to peers, Zentalis Pharmaceuticals has a valuation of -0.7834, while Prothena Corp. Plc has a valuation of -1.6907, indicating that Zentalis is relatively better positioned but still in a risky category. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.83% compared to the index's 12.22%, reinforcing the notion that it is overvalued in its current state....

View All News